First-in-human dose-escalation and expansion study (MITOPE) to evaluate mitochondrial PRX3 inhibition by RSO-021 in patients with mesothelioma and other advanced solid tumors
Dulloo, S. Fennell, D. A. Szlosarek, P. W. Lord, S. Rahman, N. M. Greystoke, A. Cunniff, B. Dzialo, J. Poile, C.
Dulloo, S.
Fennell, D. A.
Szlosarek, P. W.
Lord, S.
Rahman, N. M.
Greystoke, A.
Cunniff, B.
Dzialo, J.
Poile, C.
Citations
Altmetric:
Abstract
Description
Date
2022
Publisher
Collections
Keywords
Type
Meetings and Proceedings
Citation
Dulloo S, Fennell DA, Szlosarek PW, Thistlethwaite F, Lord S, Rahman NM, et al. First-in-human dose-escalation and expansion study (MITOPE) to evaluate mitochondrial PRX3 inhibition by RSO-021 in patients with mesothelioma and other advanced solid tumors. Annals of Oncology. 2022 Sep;33(7):S1292-S3. PubMed PMID: WOS:000866211602195.